-
Mashup Score: 0
Lipid panels, not statin prescription alone, should be reconsidered as a quality and performance measure of LDL control, according to a joint perspective from the National Lipid Association and American Society for Preventive Cardiology.During a presentation at the National Lipid Association (NLA) Scientific Sessions, Christie M. Ballantyne, MD, FACC, FACP, FAHA, FNLA, chief of the section of
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0ROSE2: Obicetrapib/ezetimibe combination further lowers LDL in statin-treated patients - 11 month(s) ago
In statin-treated patients with dyslipidemia, the combination of obicetrapib and ezetimibe further lowered LDL, according to the results of the phase 2 ROSE2 trial. As Healio previously reported, obicetrapib (NewAmsterdam Pharma), an investigational cholesteryl ester transfer protein (CETP) inhibitor, decreased LDL, non-HDL, lipoprotein(a) and apolipoprotein B and increased HDL at 8 weeks in
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: “With this data, we are moving forward with a fixed-dose combination tablet ... and we will initiate phase 3 in early 2024,” @nationallipid @LipidJournal @mdavidsonmd #cardiotwitter #NLA2023 https://t.co/iZu8LjPQlf
-
-
Mashup Score: 0
Lipid panels, not statin prescription alone, should be reconsidered as a quality and performance measure of LDL control, according to a joint perspective from the National Lipid Association and American Society for Preventive Cardiology.During a presentation at the National Lipid Association (NLA) Scientific Sessions, Christie M. Ballantyne, MD, FACC, FACP, FAHA, FNLA, chief of the section of
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: @CBallantyneMD said because of these other performance measures, CMS “recognized that to treat a chronic condition, you need to measure something, except where it comes to lipids" @nationallipid @ASPCardio @endocrinetoday #cardiotwitter #NLA2023 https://t.co/BZrvmMbWDg
-
-
Mashup Score: 0
Lipid panels, not statin prescription alone, should be reconsidered as a quality and performance measure of LDL control, according to a joint perspective from the National Lipid Association and American Society for Preventive Cardiology.During a presentation at the National Lipid Association (NLA) Scientific Sessions, Christie M. Ballantyne, MD, FACC, FACP, FAHA, FNLA, chief of the section of
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Lipid panels, not #statin prescription alone, should be reconsidered as a quality/performance measure of LDL control, according to a joint perspective from @nationallipid and @ASPCardio @CBallantyneMD @BCM_CVRI @endocrinetoday #cardiotwitter #NLA2023 https://t.co/BZrvmMbWDg
-
-
Mashup Score: 1ROSE2: Obicetrapib/ezetimibe combination further lowers LDL in statin-treated patients - 11 month(s) ago
In statin-treated patients with dyslipidemia, the combination of obicetrapib and ezetimibe further lowered LDL, according to the results of the phase 2 ROSE2 trial. As Healio previously reported, obicetrapib (NewAmsterdam Pharma), an investigational cholesteryl ester transfer protein (CETP) inhibitor, decreased LDL, non-HDL, lipoprotein(a) and apolipoprotein B and increased HDL at 8 weeks in
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
In statin-treated patients with dyslipidemia, the combination of obicetrapib and ezetimibe further lowered LDL, according to the results of the phase 2 ROSE2 trial @nationallipid @LipidJournal @mdavidsonmd #cardiotwitter #NLA2023 https://t.co/iZu8LjPQlf
-
-
Mashup Score: 0
In this Healio | Cardiology Today video exclusive, Chad Morreale, DO, discusses his presentation at the National Lipid Association Scientific Sessions: “Cardiometabolic Disease Patient – How Do I Approach Residual Risk?”Morreale, who is an NLA lipid scholar and a cardiovascular disease fellow, PGY-5, at Advocate Lutheran General Hospital, provided a case example and discussed
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: In this Healio | Cardiology Today video exclusive, Chad Morreale, DO, discusses his presentation at #NLA2023: “Cardiometabolic Disease Patient – How Do I Approach Residual Risk?” @CVOMed @AuroraCVFellows @nationallipid @endocrinetoday #cardiotwitter https://t.co/kuKKjWaYHn
-
-
Mashup Score: 2
In this Healio | Cardiology Today video exclusive, Chad Morreale, DO, discusses his presentation at the National Lipid Association Scientific Sessions: “Cardiometabolic Disease Patient – How Do I Approach Residual Risk?”Morreale, who is an NLA lipid scholar and a cardiovascular disease fellow, PGY-5, at Advocate Lutheran General Hospital, provided a case example and discussed
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: In this Healio | Cardiology Today video exclusive, Chad Morreale, DO, discusses his presentation at #NLA2023: “Cardiometabolic Disease Patient – How Do I Approach Residual Risk?” @CVOMed @AuroraCVFellows @nationallipid @endocrinetoday #cardiotwitter https://t.co/kuKKjWaYHn
-
-
Mashup Score: 0
In this Healio | Cardiology Today video exclusive, Chad Morreale, DO, discusses his presentation at the National Lipid Association Scientific Sessions: “Cardiometabolic Disease Patient – How Do I Approach Residual Risk?”Morreale, who is an NLA lipid scholar and a cardiovascular disease fellow, PGY-5, at Advocate Lutheran General Hospital, provided a case example and discussed
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
In this Healio | Cardiology Today video exclusive, Chad Morreale, DO, discusses his presentation at #NLA2023: “Cardiometabolic Disease Patient – How Do I Approach Residual Risk?” @CVOMed @AuroraCVFellows @nationallipid @endocrinetoday #cardiotwitter https://t.co/kuKKjWaYHn
-
-
Mashup Score: 0
In this Healio | Cardiology Today video exclusive, Christie M. Ballantyne, MD, FACC, FACP, FAHA, FNLA, provided a review of the NLA Scientific Session opening session, “The Latest in Lipid Lowering Therapy – It’s Not Just a Phase.”The opening session included presentations on contemporary trials in familial hypercholesterolemia, triglycerides trials, lipoprotein(a) trials and
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
In this Healio | Cardiology Today video exclusive, Daniel Soffer, MD, FNLA, discussed some of the highlights so far from the National Lipid Association Scientific Sessions #NLA2023 @nationallipid @dan_soffer #cardiotwitter https://t.co/39FB0FHwgh
-
ICYMI: In this Healio | Cardiology Today video exclusive, @CBallantyneMD provided a review of the NLA Scientific Session opening session, “The Latest in Lipid Lowering Therapy – It's Not Just a Phase.” #NLA2023 @nationallipid #cardiotwitter https://t.co/39FB0FHwgh
-
-
Mashup Score: 1
In this Healio | Cardiology Today video exclusive, Christie M. Ballantyne, MD, FACC, FACP, FAHA, FNLA, provided a review of the NLA Scientific Session opening session, “The Latest in Lipid Lowering Therapy – It’s Not Just a Phase.”The opening session included presentations on contemporary trials in familial hypercholesterolemia, triglycerides trials, lipoprotein(a) trials and
Source: www.healio.comCategories: Expert Picks, Latest HeadlinesTweet-
VIDEO: The latest in lipid-lowering therapy at NLA with Christie M. Ballantyne @CBallantyneMD good job!! Don’t forget lifestyle! https://t.co/keHjjmS2uC
-
ICYMI: In this Healio | Cardiology Today video exclusive, @CBallantyneMD provided a review of the NLA Scientific Session opening session, “The Latest in Lipid Lowering Therapy – It's Not Just a Phase.” #NLA2023 @nationallipid #cardiotwitter https://t.co/39FB0FHwgh
-
ICYMI: @CBallantyneMD said because of these other performance measures, CMS “recognized that to treat a chronic condition, you need to measure something, except where it comes to lipids" @nationallipid @ASPCardio @endocrinetoday #cardiotwitter #NLA2023 https://t.co/BZrvmMbWDg